Harvard Bioscience (HBIO)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Fiscal Year End Date: 12/31
| 03-2022 | 12-2021 | 09-2021 | 06-2021 | 03-2021 | |
| Sales | 28,778 | 33,055 | 29,663 | 29,197 | 26,989 |
| Cost of Goods | 12,601 | 13,495 | 13,355 | 12,844 | 11,558 |
| Gross Profit | 16,177 | 19,560 | 16,308 | 16,353 | 15,431 |
| Operating Expenses | 23,490 | 18,356 | 16,115 | 17,139 | 16,228 |
| Operating Income | -6,712 | 1,699 | 548 | 58 | -239 |
| Interest Expense | 384 | 379 | 373 | 377 | 411 |
| Other Income | 78 | -189 | -130 | -313 | -34 |
| Pre-tax Income | -7,018 | 1,131 | 45 | -632 | -684 |
| Income Tax | -138 | 170 | 215 | -222 | -15 |
| Net Income Continuous | -6,880 | 961 | -170 | -410 | -669 |
| Net Income | $-6,880 | $961 | $-170 | $-410 | $-669 |
| EPS Basic Total Ops | -1.70 | 0.20 | 0.00 | -0.10 | -0.20 |
| EPS Basic Continuous Ops | -1.67 | 0.24 | -0.04 | -0.10 | -0.17 |
| EPS Diluted Total Ops | -1.70 | 0.20 | 0.00 | -0.10 | -0.20 |
| EPS Diluted Continuous Ops | -1.67 | 0.24 | -0.04 | -0.10 | -0.17 |
| EBITDA(a) | $-4,794 | $3,691 | $2,497 | $2,039 | $1,740 |